Page last updated: 2024-11-04

vorinostat and E coli Infections

vorinostat has been researched along with E coli Infections in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Allavena, G1
Debellis, D1
Marotta, R1
Joshi, CS1
Mysorekar, IU1
Grimaldi, B1

Other Studies

1 other study available for vorinostat and E coli Infections

ArticleYear
A broad-spectrum antibiotic, DCAP, reduces uropathogenic Escherichia coli infection and enhances vorinostat anticancer activity by modulating autophagy.
    Cell death & disease, 2018, 07-13, Volume: 9, Issue:7

    Topics: Aminophenols; Anti-Bacterial Agents; Antineoplastic Agents; Autophagosomes; Autophagy; Cell Line, Tu

2018